Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 97

1.

Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.

Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M.

Prostate. 2019 Oct 15. doi: 10.1002/pros.23919. [Epub ahead of print]

PMID:
31614001
2.

Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Mori K, Kimura S, Parizi MK, Enikeev DV, Glybochko PV, Seebacher V, Fajkovic H, Mostafaei H, Lysenko I, Janisch F, Egawa S, Shariat SF.

Clin Genitourin Cancer. 2019 Jul 19. pii: S1558-7673(19)30225-3. doi: 10.1016/j.clgc.2019.07.009. [Epub ahead of print] Review.

PMID:
31558410
3.

Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.

Kardoust Parizi M, Enikeev D, Glybochko PV, Seebacher V, Janisch F, Fajkovic H, Chłosta PL, Shariat SF.

World J Urol. 2019 Sep 6. doi: 10.1007/s00345-019-02936-y. [Epub ahead of print]

PMID:
31493109
4.

Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis.

Janisch F, Shariat SF, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, Yang L, Glybochko PV, Rink M, Abufaraj M.

World J Urol. 2019 Jul 18. doi: 10.1007/s00345-019-02875-8. [Epub ahead of print]

PMID:
31321509
5.

Current Disease Management of Primary Urethral Carcinoma.

Janisch F, Abufaraj M, Fajkovic H, Kimura S, Iwata T, Nyirady P, Rink M, Shariat SF.

Eur Urol Focus. 2019 Jul 12. pii: S2405-4569(19)30172-5. doi: 10.1016/j.euf.2019.07.001. [Epub ahead of print] Review.

6.

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis.

Kardoust Parizi M, Abufaraj M, Fajkovic H, Kimura S, Iwata T, D'Andrea D, Karakiewicz PI, Shariat SF.

Urol Oncol. 2019 Oct;37(10):637-646. doi: 10.1016/j.urolonc.2019.06.007. Epub 2019 Jul 8. Review.

PMID:
31296421
7.

Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer.

Iwata T, Kimura S, Abufaraj M, Janisch F, Parizi MK, Haitel A, Rink M, Rouprêt M, Fajkovic H, Seebacher V, Nyirady P, Karakiewicz PI, Enikeev D, Rapoport LM, Nasu Y, Shariat SF.

Urol Oncol. 2019 Oct;37(10):774-783. doi: 10.1016/j.urolonc.2019.05.019. Epub 2019 Jun 27.

PMID:
31255543
8.

Risk stratification of upper tract urothelial carcinoma: A Review of the Current Literature.

Kardoust Parizi M, Glybochko PV, Enikeev D, Rouprêt M, Fajkovic H, Seebacher V, Shariat SF.

Expert Rev Anticancer Ther. 2019 Jun;19(6):503-513. doi: 10.1080/14737140.2019.1621753. Epub 2019 May 27.

PMID:
31131643
9.

Consultation on UTUC, Stockholm 2018: aspects of treatment.

Jung H, Giusti G, Fajkovic H, Herrmann T, Jones R, Straub M, Baard J, Osther PJS, Brehmer M.

World J Urol. 2019 May 23. doi: 10.1007/s00345-019-02811-w. [Epub ahead of print]

PMID:
31123852
10.

Enhanced Recovery after Radical Cystectomy.

Pozo C, Shariat SF, D'Andrea D, Fajkovic H, Abufaraj M.

Curr Opin Urol. 2019 May;29(3):227-238. doi: 10.1097/MOU.0000000000000594.

PMID:
30950886
11.

The interaction of gender and smoking on bladder cancer risks.

Janisch F, Shariat SF, Schernhammer E, Rink M, Fajkovic H.

Curr Opin Urol. 2019 May;29(3):249-255. doi: 10.1097/MOU.0000000000000602.

PMID:
30888973
12.

Editorial comment: gender medicine in urology.

Fajkovic H.

Curr Opin Urol. 2019 May;29(3):247-248. doi: 10.1097/MOU.0000000000000597. No abstract available.

PMID:
30789550
13.

Role of lasers in urology.

Korn SM, Hübner NA, Seitz C, Shariat SF, Fajkovic H.

Photochem Photobiol Sci. 2019 Feb 13;18(2):295-303. doi: 10.1039/c8pp00409a. Review.

PMID:
30640321
14.

Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence.

Rieken M, Kluth LA, Fajkovic H, Capitanio U, Briganti A, Krabbe LM, Margulis V, Abufaraj M, Mari A, Foerster B, Raman JD, Regelman M, Brookman-May S, Sjoberg DD, Karakiewicz PI, Shariat SF.

Clin Genitourin Cancer. 2018 Aug;16(4):e903-e908. doi: 10.1016/j.clgc.2018.03.003. Epub 2018 Mar 24.

PMID:
29653814
15.

Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.

von Landenberg N, Aziz A, von Rundstedt FC, Dobruch J, Kluth LA, Necchi A, Noon A, Rink M, Hendricksen K, Decaestecker KPJ, Seiler R, Poyet C, Fajkovic H, Shariat SF, Xylinas E, Roghmann F; Young Academic Urologists′ Working Group on Urothelial Cancer of the European Association of Urology.

Urol Oncol. 2018 May;36(5):238.e19-238.e27. doi: 10.1016/j.urolonc.2018.01.017. Epub 2018 Mar 3.

PMID:
29506940
16.

Robot-assisted partial nephrectomy: systematic review of functional results.

Foerster B, Kimura S, Vartolomei MD, Abufaraj M, Gust K, Fajkovic H, Shariat SF, Seitz C.

Curr Opin Urol. 2018 Mar;28(2):123-131. doi: 10.1097/MOU.0000000000000482.

PMID:
29278584
17.

Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy.

Özsoy M, Moschini M, Fajkovic H, Soria F, Seitz C, Klatte T, Gust K, Briganti A, Karakiewicz PI, Roupret M, Kramer G, Shariat SF.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):100-105. doi: 10.1038/s41391-017-0015-8. Epub 2017 Dec 11.

PMID:
29230007
18.

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.

Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242. doi: 10.1007/s00259-017-3858-2. Epub 2017 Oct 26.

19.

Female with bladder cancer: what and why is there a difference?

Marks P, Soave A, Shariat SF, Fajkovic H, Fisch M, Rink M.

Transl Androl Urol. 2016 Oct;5(5):668-682. Review.

20.

Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma.

Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V.

J Urol. 2017 Mar;197(3 Pt 1):580-589. doi: 10.1016/j.juro.2016.09.078. Epub 2016 Sep 23.

PMID:
27670916

Supplemental Content

Loading ...
Support Center